CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Parkview Health System, Inc. and Subsidiaries d/b/a Parkview Health
As of and for the six months ended June 30, 2017 and 2016

## Consolidated Balance Sheets (In Thousands)

Assets	 June 2017 Unaudited)	December 2016		
Current assets:				
Cash and cash equivalents	\$ 123,385	\$	100,032	
Short-term investments	307		306	
Patient accounts receivable, less allowances				
for bad debts of \$98,553 and \$79,034				
in 2017 and 2016, respectively	211,409		183,477	
Inventories	24,954		23,169	
Prepaid expenses and other current assets	28,817		25,392	
Estimated third-party payor settlements	3,606	3,960		
Total current assets	392,478		336,336	
Investments:				
Board-designated cash and investments	947,997		936,056	
Funds held by trustees	44,410		49,969	
Other investments	 795		789	
	 993,202		986,814	
Property and equipment:				
Cost	1,847,422		1,795,851	
Less accumulated depreciation and amortization	812,338		770,713	
1	1,035,084		1,025,138	
Other assets:	, ,		, ,	
Interest rate swaps	2,279		1,732	
Investments in joint ventures	1,863		2,188	
Goodwill and intangible assets, net	102,558		103,107	
Other assets	30,027		36,346	
	136,727		143,373	
Total assets	\$ 2,557,491	\$	2,491,661	

Liabilities and net assets	June 2017 (Unaudited)	December 2016
Current liabilities: Accounts payable and accrued expenses Salaries, wages, and related liabilities Accrued interest Estimated third-party payor settlements Current portion of long-term debt Total current liabilities	\$ 70,10 88,43 2,59 8,76 25,04 194,95	9 101,669 8 2,806 6 5,214 0 27,251
Noncurrent liabilities: Long-term debt, less current portion Interest rate swaps Accrued pension obligations Other	598,555 72,17' 97,29 23,669 791,689	7 73,144 1 90,826 9 24,180
Net assets: Parkview Health System, Inc. Noncontrolling interest in subsidiaries Total unrestricted net assets Temporarily restricted net assets Permanently restricted net assets Total net assets	1,524,466 31,44 1,555,900 13,39 1,54 1,570,850	2 31,367 5 1,464,584 7 13,420 8 1,544
Total liabilities and net assets	\$ 2,557,49	1 \$ 2,491,661

### Consolidated Statements of Operations and Changes in Net Assets (In Thousands)

		Three Mon			Ended			
		June 2017	e 30	2016		Jun 2017	2016	
	$\overline{\alpha}$	Jnaudited)	(1	Unaudited)	(U	(naudited)	(	Unaudited)
Revenues:		,	`	,		,	Ì	
Patient service revenue (net of contractual allowances and discounts)	\$	413,418	\$	389,405	\$	823,986	\$	766,716
Provision for bad debts		(35,284)		(32,163)		(63,119)		(66,623)
Net patient service revenue, less provision for bad debts		378,134		357,242		760,867		700,093
Capitation revenue		14,897		25,172		28,398		46,932
Other revenue		9,780		11,409		20,384		22,248
		402,811		393,823		809,649		769,273
Expenses:								
Salaries and benefits		211,692		192,734		420,990		378,324
Supplies		61,728		52,906		121,740		107,107
Purchased services		38,116		46,331		75,829		86,181
Utilities, repairs, and maintenance		14,072		13,888		28,559		28,509
Depreciation and amortization		22,307		23,753		46,229		47,040
Hospital assessment fee		9,737		9,944		20,459		19,497
Interest expense		6,225		6,734		12,640		12,874
Other		18,189		17,891		34,136		33,886
		382,066		364,181		760,582		713,418
Operating income		20,745		29,642		49,067		55,855
Nonoperating income (expense):								
Interest, dividends, and realized gains								
on sales of investments, net		6,627		9,268		12,734		9,934
Unrealized gains on investments, net		12,663		9,585		39,085		12,548
Realized and unrealized (losses) gains on interest rate swaps, net		(706)		(7,542)		1,468		(22,025)
Other		634		42		637		38
Excess of revenues over expenses		39,963		40,995		102,991		56,350
Excess of revenues over expenses attributable to noncontrolling								
interest in subsidiaries		5,378		7,093		11,909		14,094
Excess of revenues over expenses attributable to								
Parkview Health System, Inc.	\$	34,585	\$	33,902	\$	91,082	\$	42,256

# Consolidated Statements of Operations and Changes in Net Assets (continued) (In Thousands)

Three Months Ended June 30

	 2017					
	(Unaudited)					
			ntrolling	Nonce	ontrolling	
	 Total	Interest		In	terest	
Unrestricted net assets:						
Excess of revenues over expenses	\$ 39,963	\$	34,585	\$	5,378	
Distributions to noncontrolling interests	(5,121)		_		(5,121)	
Other	 9		9			
Increase in unrestricted net assets	 34,851		34,594		257	
Temporarily restricted net assets:						
Contributions	361		361		_	
Investment income	21		21		_	
Net assets released from restrictions	(175)		(175)		_	
Increase in temporarily restricted net assets	 207		207		_	
Permanently restricted net assets:						
Contributions	_		_		_	
Increase in permanently restricted net assets	 _		_			
Increase in net assets	35,058		34,801		257	
Net assets at beginning of period	1,535,792		1,504,607		31,185	
Net assets at end of period	\$ 1,570,850	\$	1,539,408	\$	31,442	

#### Six Months Ended June 30 2017

			J)	Jnaudited)		
			C	ontrolling	None	controlling
		Total		Interest	I	nterest
Unrestricted net assets:						
Excess of revenues over expenses	\$	102,991	\$	91,082	\$	11,909
Distributions to noncontrolling interests		(11,834)		_		(11,834)
Other		164		164		_
Increase in unrestricted net assets		91,321		91,246		75
Temporarily restricted net assets:						
Contributions		449		449		_
Investment income		24		24		_
Net assets released from restrictions		(496)		(496)		_
Decrease in temporarily restricted net assets	<u>-</u>	(23)		(23)		_
Permanently restricted net assets:						
Contributions		4		4		_
Increase in permanently restricted net assets		4		4		_
Increase in net assets		91,302		91,227		75
Net assets at beginning of period		1,479,548		1,448,181		31,367
Net assets at end of period	\$	1,570,850	\$	1,539,408	\$	31,442

# Consolidated Statements of Operations and Changes in Net Assets (continued) (In Thousands)

Three Months Ended June 30 2016

				2016			
	(Unaudited)						
		Total		Controlling		ncontrolling	
				Interest		Interest	
Unrestricted net assets							
Excess of revenues over expenses	\$	40,995	\$	33,902	\$	7,093	
Distributions to noncontrolling interests		(6,040)		_		(6,040)	
Other		(78)		(77)	(1)		
Increase in unrestricted net assets		34,877		33,825		1,052	
Temporarily restricted net assets							
Contributions		368		368		_	
Investment income		35		35		_	
Net assets released from restrictions		(321)		(321)		_	
Increase in temporarily restricted net assets		82		82		_	
Permanently restricted net assets							
Contributions		1		1		_	
Net assets released from restrictions		(26)		(26)		_	
Decrease in permanently restricted net assets		(25)		(25)			
Increase in net assets		34,934		33,882		1,052	
Net assets at beginning of period		1,319,822		1,291,960		27,862	
Net assets at end of period	\$	1,354,756	\$	1,325,842	\$	28,914	

#### Six Months Ended June 30 2016

	2010					
	(Unaudited)					
			(	Controlling	No	ncontrolling
		Total		Interest	Interest	
Unrestricted net assets						
Excess of revenues over expenses	\$	56,350	\$	42,256	\$	14,094
Distributions to noncontrolling interests		(13,080)		_		(13,080)
Other		(49)		(49)		_
Increase in unrestricted net assets		43,221		42,207		1,014
Temporarily restricted net assets						
Contributions		470		470		_
Investment income		64		64		_
Net assets released from restrictions		(433)		(433)		_
Increase in temporarily restricted net assets		101		101		-
Permanently restricted net assets						
Contributions		1		1		_
Net assets released from restrictions		(26)		(26)		_
Decrease in permanently restricted net assets		(25)		(25)		_
Increase in net assets		43,297		42,283		1,014
Net assets at beginning of period		1,311,459		1,283,559		27,900
Net assets at end of period	\$	1,354,756	\$	1,325,842	\$	28,914

### Consolidated Statements of Cash Flows

(In Thousands)

	Six Months Ended June 30			
		2017	2016	
	J)	Jnaudited)	(Unaudited)	
Cash flow from operating activities:				
Increase in net assets	\$	91,302 \$	43,297	
Adjustments to reconcile increase in net assets to				
net cash provided by operating activities:				
Provision for bad debts		63,118	66,623	
Depreciation and amortization		46,229	47,040	
Contributions restricted for capital		(449)	(471)	
Undistributed (earnings) loss from alternative investments		(5,874)	8,329	
Unrealized (gains) losses on interest rate swaps, net		(1,535)	22,159	
Amortization of deferred financing costs and discount		(617)	(285)	
Loss (gain) from disposal of property and equipment		76	(37)	
Changes in operating assets and liabilities:			( /	
Patient accounts receivable		(91,051)	(69,757)	
Inventories		(1,785)	(975)	
Prepaid expenses and other current assets		(3,419)	(6,222)	
Trading securities, net		(515)	(58,352)	
Accounts payable, accrued expenses, and other current liabilities		(34,689)	(26,879)	
Estimated third-party payor settlements		3,906	5,685	
Accrued pension obligations		6,464	6,531	
Collateral posted on swaps, net		0,404	(7,227)	
Other		17,016	8,361	
Net cash provided by operating activities			37,820	
Net cash provided by operating activities		88,177	37,820	
Cash flow from investing activities:				
Property and equipment additions, net		(53,847)	(30,148)	
Business acquisitions, net of cash acquired		(23)	(26)	
Proceeds from sale of property and equipment		17	324	
Net cash used in investing activities		(53,853)	(29,850)	
Cash flow from financing activities:		(20.150)	(10.202)	
Principal payments of long-term debt		(20,150)	(19,392)	
Proceeds from issuance of long-term debt		21,700	323	
Payments of capital lease obligations		(1,215)	(2,593)	
Distributions to noncontrolling interests		(11,834)	(13,080)	
Contributions restricted for capital		449	471	
Other		79	112	
Net cash used in financing activities		(10,971)	(34,159)	
Increase (decrease) in cash and cash equivalents		23,353	(26,189)	
Cash and cash equivalents at beginning of period		100,032	154,487	
Cash and cash equivalents at end of period	\$	123,385 \$	128,298	
Schedule of noncash investing and financing activities	•	<b>5/7</b> ¢	F12	
Assets acquired through capital leases	\$	567 \$	512	